Natalie Brunette

TL;DR: In this article, the authors demonstrate the capacity of a subunit vaccine, comprising the SARS-CoV-2 spike protein receptor-binding domain displayed on an I53-50 protein nanoparticle scaffold (hereafter designated RBD-NP), to stimulate robust and durable neutralizing-antibody responses.

TL;DR: In this paper, a clinical stage multivalent SARS-CoV-2 spike receptor-binding domain nanoparticle (RBD-NP) vaccine was used to protect mice from SARS CoV 2 challenge after a single immunization.

TL;DR: In this article, an engineered sequence variant of RBD that exhibits high-yield manufacturability, high-affinity binding to ACE2, and enhanced immunogenicity after a single dose in mice compared to the Wuhan-Hu-1 variant used in current vaccines.

TL;DR: In this article, the authors used previously reported deep mutational scanning (DMS) data to guide the design of stabilized variants of the receptor-binding domain (RBD) that have been identified as a linoleic acid binding pocket.

TL;DR: In this article , the authors compared five clinically relevant adjuvants in mice-alum, AS03 (a squalene-based adjuvant supplemented with α-tocopherol), AS37 (a TLR7 ligand emulsified in alum), CpG1018 (TLR9), O/W 1849101, and AS03 with a subunit vaccine under clinical development.